US Edition
REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS
VESALIUS-CV trial showed Repatha cut first major cardiovascular events by 31% in 3,655 high-risk diabetes patients without significant atherosclerosis over 4.8 years.
- On Saturday, Amgen announced that Repatha, when added to statins or other lipid-lowering treatments, reduced the risk of first major cardiovascular events by 31% in high-risk diabetes patients without prior heart attack or stroke.
- Cardiovascular disease remains the leading global cause of death, with high LDL-C functioning as a primary, modifiable risk factor that makes earlier, more intensive lowering critical for high-risk individuals.
- A new subgroup analysis of 3,655 patients from the VESALIUS-CV trial found Repatha reduced the relative risk of a composite of coronary heart disease death, myocardial infarction, or ischemic stroke by 31% compared with placebo.
- Researchers concluded the data demonstrates the "value of intensification of lipid-lowering therapy" earlier in disease progression, suggesting current LDL-C targets for high-risk primary prevention patients may be insufficient.
- Editorialists Philip Greenland, MD, and Donald M. Lloyd-Jones, MD, of Northwestern University noted that while short-term safety appeared sound, "significant questions also persist about cost-effectiveness" in younger or lower-risk patients.
32 Articles
32 Articles
Evolocumab reduces cardiac events in high-risk diabetic patients
The cholesterol-lowering therapy evolocumab reduced the risk of major adverse cardiac events by nearly one-third among patients who had no known significant atherosclerosis and had diabetes, according to a study presented at the American College of Cardiology's Annual Scientific Session.
PCSK9 Drug Prevents First Heart Events in Diabetes Patients Without Atherosclerosis
(MedPage Today) -- NEW ORLEANS -- Evolocumab (Repatha) reduced risk of a first major cardiovascular (CV) event in patients with diabetes but no known atherosclerosis in a substudy of the VESALIUS-CV trial. The PCSK9 inhibitor cut relative risk...
Evolocumab Cuts Cardiac Risk in Diabetics Without Atherosclerosis: Study
Archyde A modern analysis of the VESALIUS-CV trial reveals that evolocumab, a PCSK9 inhibitor, significantly reduces the risk of major cardiac events – by nearly one-third – in high-risk diabetic patients ... Read More The post Evolocumab Cuts Cardiac Risk in Diabetics Without Atherosclerosis: Study appeared first on Archyde.
Evolocumab reduces risk of cardiac events in patients with no known atherosclerosis and diabetes
The cholesterol-lowering therapy evolocumab reduced the risk of major adverse cardiac events by nearly one-third among patients who had no known significant atherosclerosis and had diabetes, according to a study presented at the American College of Cardiology’s Annual Scientific Session (ACC.26; 28–30 March, New Orleans, USA). The study, a subgroup analysis of the VESALIUS-CV trial, involved over 3,600 patients with diabetes who were not previou…
Coverage Details
Bias Distribution
- 88% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
